European Economic
and Social Committee
Veterinary medicinal products / EMA
Other relevant EESC opinions:
- INT/712 Fees payable/EMA (rapporteur: Ms Heinisch)
- INT/658 Clinical trials on medicinal products for human use (rapporteur : Ms Kössler)
- INT/665 Innovation and health package (rapporteur: Mr Stantic)
- INT/642 Prices of medicinal products for human use (rapporteur: Ms Kössler)
- INT/471 Pharmacovigilance –Community code relating to medicinal products for human use (rapporteur: Mr Cedrone)
- INT/472 Prevention of falsified medicinal products (rapporteur: Mr Morgan)
- INT/470 Pharmacovigilance – Community Regulation – medicinal products for human and veterinary use (rapporteur: Ms Gauci)
- INT/475 Medicinal products for human and veterinary use - European Medicines Agency (rapporteur: Mr Cedrone)
- INT/469 Medicinal products for human use – Community code (rapporteur: Ms Heinisch)
Recommended for you
Packaging and labelling of veterinary medicinal products – transitional rules
Opinion
Since the Committee endorses the content of the proposal and feels that it requires no comment on its part, it decided, at its 568th plenary session of 23 and 24 March 2022 (meeting of 23 March), to…
Medicinal products for human and investigational use / Derogations
Opinion
The EESC:welcomes this package of measures;recognises that need to pay particular attention to the situation of smaller EU Member States, Cyprus, Ireland and Malta in particula;stresses in particular…
Fees payable / EMA
Opinion
Securing Europe’s medicine supply: envisioning a Critical Medicines Act
Opinion
The Covid 19-pandemic has drawn attention to the role of the pharmaceutical industry and to production, availability and affordability of medicines and medicinal products on the European market…
Critical Medicines Act
Opinion
Key pointsThe EESC:recommends significantly increasing funding to support the objectives of the Critical Medicines Act. A dedicated European fund should be established for starting materials, Active…